Abstract
This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].
Keywords: Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative colitis.
Current Drug Targets
Title:Pharmacokinetics in IBD: Ready for Prime Time?
Volume: 15 Issue: 11
Author(s): Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, Amelie Moreau, Jean Marc Phelip, Christian Genin, Dominique Lamarque and Stephane Paul
Affiliation:
Keywords: Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative colitis.
Abstract: This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].
Export Options
About this article
Cite this article as:
Roblin Xavier, Rinaudo Melanie, Sparrow Peter Miles, Moreau Amelie, Phelip Marc Jean, Genin Christian, Lamarque Dominique and Paul Stephane, Pharmacokinetics in IBD: Ready for Prime Time?, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140829153509
DOI https://dx.doi.org/10.2174/1389450115666140829153509 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management
Current Medicinal Chemistry Omega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?
Current Neuropharmacology Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Platelets and Platelet-Derived Microparticles in Vascular Inflammatory Disease
Inflammation & Allergy - Drug Targets (Discontinued) C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Mechanistic Approach to Understanding Psychosis Risk in Velocardiofacial Syndrome
Current Pediatric Reviews Evaluation of Disease Severity and Health-Related Quality of Life in Patients with Rheumatoid Arthritis Undergoing Total Knee Arthroplasty
Current Rheumatology Reviews Editorial [Hot topic: NKT Cell Therapy (Guest Editor: Masashi Emoto)]
Current Immunology Reviews (Discontinued) Engineered Inorganic Nanoparticles for Drug Delivery Applications
Current Drug Metabolism New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Alefacept - A Drug Review
Reviews on Recent Clinical Trials Applications of Barton-McCombie Reaction in Total Syntheses
Current Organic Synthesis New Therapeutic Interventions in Airway Inflammatory and Allergic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry The Roles of Apoptosis in Wound Healing and Pulmonary Fibrosis
Drug Design Reviews - Online (Discontinued)